Literature DB >> 18058038

Hepatitis B viral factors and clinical outcomes of chronic hepatitis B.

Chih-Lin Lin1, Jia-Horng Kao.   

Abstract

Hepatitis B virus (HBV) infection is an important health problem and the major cause of chronic hepatitis, cirrhosis as well as hepatocellular carcinoma (HCC) worldwide. The natural history of chronic HBV infection can be divided into 4 dynamic phases in HBV carriers who acquire the virus early in life. In general, the frequency and severity of hepatitis flares in the immune clearance or reactivation phase predict disease progression in HBV carriers, and early HBeAg seroconversion typically confers a favorable outcome. In contrast, late or absent HBeAg seroconversion after multiple hepatitis flares accelerates the progression of chronic hepatitis to cirrhosis. Recently, several hepatitis B viral factors predictive of clinical outcomes have been identified. For example, serum HBV DNA level at enrollment is the best predictor of adverse outcomes (cirrhosis, HCC and death from liver disease) in adults with chronic HBV infection. In addition, HBV genotype C, basal core promoter (BCP) mutant and pre-S deletion mutant are associated with increased risk of HCC development. In conclusion, hepatitis B viral factors such as serum HBV DNA level, genotype and mutants have already been clarified to influence disease progression of chronic hepatitis B. Further studies are needed to investigate the pathogenic mechanism of each viral factor.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18058038     DOI: 10.1007/s11373-007-9225-8

Source DB:  PubMed          Journal:  J Biomed Sci        ISSN: 1021-7770            Impact factor:   8.410


  26 in total

1.  Temporal acquisition of sequential mutations in the enhancer II and basal core promoter of HBV in individuals at high risk for hepatocellular carcinoma.

Authors:  Xin Bai; Yu Zhu; Yan Jin; Xia Guo; Gengsun Qian; Taoyang Chen; Jing Zhang; Jinbing Wang; John D Groopman; Jianren Gu; Hong Tu
Journal:  Carcinogenesis       Date:  2010-09-28       Impact factor: 4.944

Review 2.  Hepatitis B virus genotypes and variants.

Authors:  Chih-Lin Lin; Jia-Horng Kao
Journal:  Cold Spring Harb Perspect Med       Date:  2015-05-01       Impact factor: 6.915

Review 3.  Clinical utility of complex mutations in the core promoter and proximal precore regions of the hepatitis B virus genome.

Authors:  Young Min Park
Journal:  World J Hepatol       Date:  2015-01-27

Review 4.  Hepatitis B virus infection: An insight into infection outcomes and recent treatment options.

Authors:  Faseeha Noordeen
Journal:  Virusdisease       Date:  2015-04-05

5.  Clinical relevance and public health significance of hepatitis B virus genomic variations.

Authors:  Guang-Wen Cao
Journal:  World J Gastroenterol       Date:  2009-12-14       Impact factor: 5.742

6.  Combined effects of p53 and MDM2 polymorphisms on susceptibility and surgical prognosis in hepatitis B virus-related hepatocellular carcinoma.

Authors:  Yun Yang; Tian Xia; Ning Li; Jin Zhang; Yuan Yang; Wenming Cong; Qiang Deng; Ke Lan; Weiping Zhou
Journal:  Protein Cell       Date:  2012-12-22       Impact factor: 14.870

7.  Retrospective study of the prevalence and clinical significance of hepatitis B virus precore and basal core promoter variants.

Authors:  Meaghan O'Brien; Adara Casselman; Gerry Smart; Ainsley Gretchen; Kelly Kaita; Kamran Kadkhoda
Journal:  Can J Gastroenterol Hepatol       Date:  2015-09-24

8.  Genetic analysis of complement component 9 (C9) polymorphisms with clearance of hepatitis B virus infection.

Authors:  Joon Seol Bae; Charisse Flerida A Pasaje; Byung Lae Park; Hyun Sub Cheong; Jeong-Hyun Kim; Tae Joon Park; Jason Yongha Kim; Jin Sol Lee; In Song Koh; Hyo-Suk Lee; Yoon Jun Kim; Hyoung Doo Shin
Journal:  Dig Dis Sci       Date:  2011-03-05       Impact factor: 3.199

Review 9.  Functions of autophagy in normal and diseased liver.

Authors:  Mark J Czaja; Wen-Xing Ding; Terrence M Donohue; Scott L Friedman; Jae-Sung Kim; Masaaki Komatsu; John J Lemasters; Antoinette Lemoine; Jiandie D Lin; Jing-hsiung James Ou; David H Perlmutter; Glenn Randall; Ratna B Ray; Allan Tsung; Xiao-Ming Yin
Journal:  Autophagy       Date:  2013-05-22       Impact factor: 16.016

10.  Huo-Luo-Xiao-Ling Dan modulates antigen-directed immune response in adjuvant-induced inflammation.

Authors:  Rajesh Rajaiah; David Y-W Lee; Zhongze Ma; Arthur Y Fan; Lixing Lao; Harry H S Fong; Brian M Berman; Kamal D Moudgil
Journal:  J Ethnopharmacol       Date:  2009-03-04       Impact factor: 4.360

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.